journal
MENU ▼
Read by QxMD icon Read
search

Bone Marrow Transplantation

journal
https://www.readbyqxmd.com/read/30232415/intrabone-transplant-provides-full-stemness-of-cord-blood-stem-cells-with-fast-hematopoietic-recovery-and-low-gvhd-rate-results-from-a-prospective-study
#1
Francesca Bonifazi, Elisa Dan, Myriam Labopin, Mariarosaria Sessa, Viviana Guadagnuolo, Martina Ferioli, Simonetta Rizzi, Sabrina De Carolis, Barbara Sinigaglia, Maria Rosa Motta, Andrea Bontadini, Valeria Giudice, Giovanni Martinelli, Mario Arpinati, Michele Cavo, Massimiliano Bonafé, Gianluca Storci
Umbilical Cord Blood (UCB) represents a valid option for patients with hematopoietic malignancies lacking an HLA matched donor. To overcome the limitation of the low stem cell dose of UCB, the intrabone (IB) route has been proposed. We report the results of a prospective study on a poor-prognosis cohort of 23 patients receiving intrabone single UCB transplant (Clinicaltrials.gov NCT00886522). Cumulative incidence of hematological recovery at day 90 was 82 ± 9% (ANC > 0.5 × 109 /L) and 70 ± 10% (platelet > 50 × 109 /L) and correlated with CD34 + cells in the graft...
September 19, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/30232414/donor-specific-anti-hla-antibodies-in-unrelated-hematopoietic-cell-transplantation-for-non-malignant-disorders
#2
LETTER
Ann Woolfrey, Tao Wang, Stephanie J Lee, Michael D Haagenson, Ge Chen, Katharina Fleischhauer, John Horan, Katharine Hsu, Michael Verneris, Stephen R Spellman, Marcelo Fernandez-Vina
No abstract text is available yet for this article.
September 19, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/30232413/correction-the-european-society-for-blood-and-marrow-transplantation-ebmt-consensus-guidelines-for-the-detection-and-treatment-of-donor-specific-anti-hla-antibodies-dsa-in-haploidentical-hematopoietic-cell-transplantation
#3
Stefan O Ciurea, Kai Cao, Marcelo Fernandez-Vina, Piyanuch Kongtim, Monzr Al Malki, Ephraim Fuchs, Leo Luznik, Xiao-Jun Huang, Fabio Ciceri, Franco Locatelli, Franco Aversa, Luca Castagna, Andrea Bacigalupo, Massimo Martelli, Didier Blaise, Rupert Handgretinger, Denis-Claude Roy, Paul O'Donnell, Asad Bashey, Hillard M Lazarus, Karen Ballen, Bipin N Savani, Mohamad Mohty, Arnon Nagler
The original version of this Article contained a typographical error in the spelling of the author Marcelo Fernandez-Vina, which was incorrectly given as Marcelo Fernadez-Vina. This has now been corrected in the PDF and HTML versions of the Article.
September 19, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/30214010/longstanding-alopecia-and-nail-dystrophy-are-associated-with-more-severe-overall-chronic-graft-versus-host-disease-in-adults
#4
LETTER
Jason S Naftulin, Lauren R Penzi, Athena Manatis-Lornell, Mariko R Yasuda, Martina L Porter, Arturo Saavedra, Maryanne Makredes Senna
No abstract text is available yet for this article.
September 13, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/30181580/veno-occlusive-disease-after-high-dose-busulfan-melphalan-in-neuroblastoma
#5
Tal Schechter, Evelio Perez-Albuerne, Tiffany F Lin, Meredith S Irwin, Mohammed Essa, Ami V Desai, Haydar Frangoul, Gregory Yanik, L Lee Dupuis, David Jacobsohn, Morris Kletzel, Mark Ranalli, Sandeep Soni, Alix E Seif, Stephan Grupp, Christopher C Dvorak
Survival for high-risk neuroblastoma patients is still suboptimal. Although stem cell transplantation (SCT) is used, there is no consensus as to which conditioning regimen has the greatest efficacy and fewest toxicities. We assessed the incidence of and risk for hepatic veno-occlusive disease (VOD) for neuroblastoma patients who underwent autologous SCT with busulfan and melphalan (BuMel) at eight centers following Children's Oncology Group (COG)-based induction chemotherapy. Data regarding the patients, SCT characteristics, busulfan steady-state concentrations, incidence of VOD, and survival were evaluated...
September 4, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/30171225/registries-and-artificial-intelligence-investing-in-the-future-of-hematopoietic-cell-transplantation
#6
LETTER
Ibrahim N Muhsen, Madan Jagasia, Amir Ahmed Toor, Shahrukh K Hashmi
No abstract text is available yet for this article.
August 31, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/30171224/a-dynamical-systems-perspective-on-chimeric-antigen-receptor-t-cell-dosing
#7
REVIEW
Amir A Toor, Alden Chesney, Jamal Zweit, Jason Reed, Shahrukh K Hashmi
Chimeric antigen receptor T cells (CAR T cells) are dosed similarly to donor lymphocyte infusions following hematopoietic cell transplantation. However, the mechanism driving proliferation in CAR T cells is distinct from conventional T cells. As such there are quantitative differences in the antigen response of these engineered cells when compared with conventional T cells. In this perspective paper the logistic equation of growth is used to develop a mathematical basis for understanding the difference between CAR T cell and conventional T cell response to antigen burden...
August 31, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/30171223/associations-between-febrile-neutropenia-related-parameters-and-the-risk-of-acute-gvhd-or-non-relapse-mortality-after-allogeneic-hematopoietic-stem-cell-transplantation
#8
Kazuaki Kameda, Shun-Ichi Kimura, Yukiko Misaki, Kazuki Yoshimura, Ayumi Gomyo, Jin Hayakawa, Masaharu Tamaki, Machiko Kusuda, Yu Akahoshi, Tomotaka Ugai, Yuko Ishihara, Koji Kawamura, Kana Sakamoto, Aki Tanihara, Hidenori Wada, Miki Sato, Kiriko Terasako-Saito, Misato Kikuchi, Hideki Nakasone, Shinichi Kako, Yoshinobu Kanda
Infection and inflammation can induce acute graft-vs.-host disease (aGVHD). We hypothesized that febrile neutropenia early after allogeneic hematopoietic cell transplantation (HCT) would increase the risk of aGVHD and non-relapse mortality (NRM). We retrospectively evaluated the impact of fever, C-reactive protein (CRP) concentration and blood stream infection (BSI) early after HCT on the incidence of grade II-IV aGVHD and NRM in 227 patients. Within 7 days after HCT, 91 (40.1%) patients experienced fever for at least 2 days (early-FN group)...
August 31, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/30171222/high-dose-benda-eam-versus-beam-in-patients-with-relapsed-refractory-classical-hodgkin-lymphoma-undergoing-autologous-stem-cell-transplantation
#9
LETTER
Erica S Tsang, Diego Villa, Federica Loscocco, Giuseppe Visani, Maryse Power, Barbara Guiducci, Cristina Clissa, Kevin Song, Cynthia Toze, Yasser Abou Mourad, Heather Sutherland, David Sanford, Stephen H Nantel, Laurie H Sehn, David W Scott, Kerry J Savage, Joseph M Connors, Alina S Gerrie, Alessandro Isidori
No abstract text is available yet for this article.
August 31, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/30171221/analysis-of-bmt-ctn-0201-and-0901-samples-did-not-reproduce-the-reported-association-between-recipient-reg3a-rs7588571-and-chronic-gvhd
#10
LETTER
Armin Rashidi, Ryan Shanley, Claudio Anasetti, Edmund K Waller, Bart L Scott, Bruce R Blazar, Daniel J Weisdorf
No abstract text is available yet for this article.
August 31, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/30135464/end-of-life-care-for-older-aml-patients-relapsing-after-allogeneic-stem-cell-transplant-at-a-dedicated-cancer-center
#11
Richard J Lin, Theresa A Elko, Miguel-Angel Perales, Koshy Alexander, Ann A Jakubowski, Sean M Devlin, Parastoo B Dahi, Esperanza B Papadopoulos, Virginia M Klimek, Sergio A Giralt, Judith E Nelson
Older patients with acute myelogenous leukemia (AML) are at increased risk for mortality and morbidity. While allogeneic stem cell transplantation may provide cure in some patients, many still relapse after transplant and are then left with limited therapeutic options and poor survival. Moreover, the quality of the end-of-life care for these patients has not been previously reported. We describe here the end-of-life experience of a cohort of 72 older patients with AML who relapsed after first allogeneic stem cell transplant at our dedicated cancer center...
August 22, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/30135463/correction-population-pharmacokinetics-of-fludarabine-in-patients-with-aplastic-anemia-and-fanconi-anemia-undergoing-allogeneic-hematopoietic-stem-cell-transplantation
#12
E Mohanan, J C Panetta, K M Lakshmi, E S Edison, A Korula, N A Fouzia, A Abraham, A Viswabandya, V Mathews, B George, A Srivastava, P Balasubramanian
This article was originally published under a CC BY-NC-ND 4.0 license, but has now been made available under a CC BY 4.0 license. The PDF and HTML versions of the article have been modified accordingly.
August 22, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/30131507/severe-immune-related-complications-early-after-allogeneic-hematopoietic-cell-transplantation-for-nivolumab-pretreated-lymphoma
#13
LETTER
Masatomo Kuno, Ayumu Ito, Takashi Tanaka, Yoshihiro Inamoto, Saiko Kurosawa, Sung-Won Kim, Takahiro Fukuda
No abstract text is available yet for this article.
August 21, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/30127467/clinicopathologic-characteristics-of-secondary-squamous-cell-carcinoma-of-head-and-neck-in-survivors-of-allogeneic-hematopoietic-stem-cell-transplantation-for-hematologic-malignancies
#14
Chakra P Chaulagain, Kellie A Sprague, Monika Pilichowska, Janet Cowan, Andreas K Klein, Esha Kaul, Kenneth B Miller
The risk of late complications including secondary malignancies is increased in long-term survivors of allogeneic hematopoietic stem cell transplants (HSCT). There is limited literature on the biological behavior and clinical features of squamous cell carcinoma (SCC) of head and neck post-HSCT. We present the clinical and pathologic characteristics on six patients who were diagnosed with SCC while in remission following an allogeneic HSCT. Median follow-up was 8 years. Five patients (83%) developed SCC of tongue and one developed esophageal SCC...
August 20, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/30127466/clinical-effects-of-recombinant-thrombomodulin-and-defibrotide-on-sinusoidal-obstruction-syndrome-after-allogeneic-hematopoietic-stem-cell-transplantation
#15
Kimikazu Yakushijin, Takayuki Ikezoe, Chikako Ohwada, Kazuko Kudo, Hiroshi Okamura, Hiroaki Goto, Hiromasa Yabe, Atsushi Yasumoto, Hideyuki Kuwabara, Shiro Fujii, Kumiko Kagawa, Masao Ogata, Yasushi Onishi, Akio Kohno, Koichi Watamoto, Nobuhiko Uoshima, Daisuke Nakamura, Shuichi Ota, Yasunori Ueda, Tatsuo Oyake, Kazutoshi Koike, Ishikazu Mizuno, Hiroatsu Iida, Yoshio Katayama, Hiroatsu Ago, Koji Kato, Atsuo Okamura, Atsushi Kikuta, Takahiro Fukuda
Sinusoidal obstruction syndrome (SOS) is a lethal complication after hematopoietic stem cell transplantation (HSCT). Defibrotide (DF) is the only drug internationally recommended for SOS treatment in Western countries. Recombinant human soluble thrombomodulin (rhTM), which is promising for the treatment of patients with disseminated intravascular coagulation, is also reported to be potentially effective for SOS. To clarify the safety and efficacy of DF and rhTM, we conducted a retrospective survey of these agents in Japan...
August 20, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/30127465/the-significance-of-peri-transplantation-minimal-residual-disease-assessed-by-multiparameter-flow-cytometry-on-outcomes-for-adult-aml-patients-receiving-haploidentical-allografts
#16
Jing Liu, Rui Ma, Yan-Rong Liu, Lan-Ping Xu, Xiao-Hui Zhang, Huan Chen, Yu-Hong Chen, Feng-Rong Wang, Wei Han, Yu-Qian Sun, Chen-Hua Yan, Fei-Fei Tang, Xiao-Dong Mo, Kai-Yan Liu, Qiao-Zhen Fan, Xiao-Jun Huang, Ying-Jun Chang
A retrospective study (n = 460) was performed to assess the relationship between minimal residual disease (MRD) and transplant outcomes in a haplo-stem cell transplantation (SCT) setting. Patients from the pre-MRDneg group and the pre-MRDpos group had comparable outcomes. Compared to post-MRDneg patients, post-MRDpos patients had a higher incidence of relapse (100.0% vs. 8.3%, p < 0.001), lower incidences of overall survival (OS) (16.9% vs. 78.2%, p < 0.001) and leukemia-free survival (LFS) (0% vs...
August 20, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/30127464/health-care-utilization-and-cost-among-pediatric-patients-receiving-unrelated-donor-allogeneic-hematopoietic-cell-transplantation
#17
Wallace Bourgeois, Angela Ricci, Zhezhen Jin, Matt Hall, Diane George, Monica Bhatia, James Garvin, Prakash Satwani
The costs associated with allogeneic hematopoietic cell transplantation (alloHCT) are high. Differences in costs and healthcare utilization among potential donor sources for alloHCT are not well characterized in pediatric recipients of alloHCT. One potential reason for these high costs could be the donor source of hematopoietic cells. In this retrospective study, inpatient costs, outpatient costs, and markers of healthcare utilization associated with unrelated donor alloHCT for malignant and non-malignant disease were analyzed for 131 pediatric patients during the first year post-transplant, for whom the donor sources were 38% umbilical cord blood (UCB), 14% unmanipulated peripheral blood stem cell (PBSC), 26% bone marrow (BM), and 22% PBSC with CD-34 selection...
August 20, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/30116019/graft-versus-leukaemia-effect-post-fludarabine-melphalan-and-alemtuzumab-reduced-intensity-allogeneic-stem-cell-transplantat-in-hiv-infected-patient-with-acute-myeloid-leukaemia
#18
A Kanellopoulos, M Kaparou, E Xenou, S Paneesha, B Kishore, R Lovell, K Holder, J Suhr, L Baker, L Ryan, E Nikolousis
Allogeneic stem cell transplantation (Allo-HSCT) is sine qua non to cure high-risk acute myeloid leukaemia (AML). In spite the advent of highly active antiretroviral treatment, HIV-infected patients display a remarkable risk for haematological neoplasms such as non-Hodgkin lymphomas, Hodgkin lymphoma and acute leukaemia. Several case series have confirmed the efficacy of the autologous stem cell transplantation for the treatment of non-Hodgkin lymphomas in the HIV setting. Nonetheless, there is a paucity of data for the role of the Allo-HSCT in HIV-infected individuals with haematological malignancies...
August 16, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/30116018/methods-and-role-of-minimal-residual-disease-after-stem-cell-transplantation
#19
Marco Ladetto, Sebastian Böttcher, Nicolaus Kröger, Michael A Pulsipher, Peter Bader
Relapse is the major cause of treatment failure after stem cell transplantation. Despite the fact that relapses occurred even if transplantation was performed in complete remission, it is obvious that minimal residual disease is present though not morphologically evident. Since adaptive immunotherapy by donor lymphocyte infusion or other novel cell therapies as well as less toxic drugs, which can be used after transplantation, the detection of minimal residual disease (MRD) has become a clinical important variable for outcome...
August 16, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/30116017/safety-of-mogamulizumab-for-relapsed-atl-after-allogeneic-hematopoietic-cell-transplantation
#20
LETTER
Yoshitaka Inoue, Shinya Endo, Naofumi Matsuno, Yoshitaka Kikukawa, Takafumi Shichijo, Kenichi Koga, Ayumi Takaki, Kouta Iwanaga, Nao Nishimura, Shigeo Fuji, Takahiro Fukuda, Kisato Nosaka, Masao Matsuoka
No abstract text is available yet for this article.
August 16, 2018: Bone Marrow Transplantation
journal
journal
20054
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"